We are live on ! Find out more
CMPI

Checkmate Pharmaceuticals, Inc. Common Stock
CMPI

Delisted

CMPI was delisted on the 27th of May, 2022.

Back to rankings

0 hedge funds and large institutions have $0 invested in Checkmate Pharmaceuticals, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 26 → 0 (-26)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $54.8M → $0 (-$54.8M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 26

Holders
–
Holders Change
-26
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
26
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
MVM
Medicxi Ventures Management
Jersey
-$12.5M
2
VP
venBio Partners
California
-$11.7M
3
SI
Sofinnova Investments
California
-$11.5M
4
NHAS
Novo Holdings A/S
Denmark
-$6.9M
5
OFM
Omega Fund Management
Massachusetts
-$4.26M

CMPI Hedge Fund Activity: Q2 2022 in Review

0 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) for Q2 2022, worth a combined $0 — down 100% from $54.8M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of CMPI and 0 opened new positions — a net loss of 26 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Medicxi Ventures Management, exiting entirely with an estimated $12.5M sold.

  • 0 institutional investors held Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) as of Q2 2022, down from 26 in Q1 2022.
  • Funds reported $0 of Checkmate Pharmaceuticals, Inc. Common Stock stock for Q2 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Checkmate Pharmaceuticals, Inc. Common Stock positions in Q2 2022 and 26 closed out, a net change of -26 holders.
  • The largest Checkmate Pharmaceuticals, Inc. Common Stock seller in Q2 2022 was Medicxi Ventures Management, an estimated $12.5M sold.

Based on aggregated 13F filings for Q2 2022.